skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


adevelopment partner pharma intelligence






clinical research organizations




marketing agencies




View Less



HBW Insight : コンシューマーヘルスケア産業のニュース

HBW Insightでは、市販薬(OTC)、ビタミンなどのサプリメント(栄養補助食品)、化粧品、衛生用品やスキンケアなどコンシューマーヘルスケア産業のニュースをワンストップでお届けします。ビジネスの動向だけでなく、規制や法律に関しても専門アナリストの分析と見解を交えてお伝えします。今後ますますグローバル化する業界の機会とリスクを予測するのに役立ちます。

Key benefits:

  • 世界のコンシューマー ヘルスケア産業を把握
  • 市場の最新ニュースと 予測を誰よりもはやく
  • 国際競争力を強化する独自のニュースと分析

Scrip: 世界の医療用医薬品&製薬産業に関するニュース


Key benefits:

  • ジャーナリストによる世界の医薬品市場動向
  • 国際競争力を強化する独自のニュースと分析
  • 製薬業界の<br>最前線が分かる

Generics Bulletin: ジェネリック&バイオシミラーニュース

インフォーマ・ファーマインテリジェンスのGenerics Bulletinは、過去15年間にわたってジェネリック医薬品(後発医薬品)、バイオシミラー(バイオ後続品)、付加価値医薬品業界の情報源として多くの方に読まれてきました。最新の規制、法律、市場動向を把握し、潜在的な脅威と機会の予測にお役立てください。

Key benefits:

  • 世界のジェネリック& バイオシミラーを把握
  • 国際競争力を強化する独自のニュースと分析
  • オンラインでアクセスできるから簡単&便利


  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Multiple Molecules See UK Prices More Than Double In December

    By David Wallace 18 Jan 2022


    WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

    By Scrip Team 18 Jan 2022


    More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

    By Joseph Haas 17 Jan 2022


    Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    17 Jan 2022


    In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    A Deep Dive Into The Game-Changing Drugs For Skin Diseases

    By Scrip Team 17 Jan 2022


    Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

    14 Jan 2022


    Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

    By Alaric DeArment 10 Jan 2022


    At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    10 Jan 2022


    In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

    By Alaric DeArment 05 Jan 2022


    The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Five (Non-COVID) Clinical Trial Misses Of 2021

    By Alex Shimmings 04 Jan 2022


    The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

    By Andrew McConaghie 23 Dec 2021


    MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage

    By Vibha Ravi 22 Dec 2021


    Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

    01 Dec 2021


    Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

    01 Dec 2021


    Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    ANI Pharmaceuticals Completes $210m Novitium Acquisition

    By Chloe Kent 30 Nov 2021


    ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.